182 related articles for article (PubMed ID: 14679070)
21. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.
Ujihara N; Daw K; Gianani R; Boel E; Yu L; Powers AC
Diabetes; 1994 Aug; 43(8):968-75. PubMed ID: 8039604
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the humoral immune response to glutamic acid decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and/or type 1 diabetes.
Ronkainen MS; Härkönen T; Perheentupa J; Knip M
Eur J Endocrinol; 2005 Dec; 153(6):901-6. PubMed ID: 16322397
[TBL] [Abstract][Full Text] [Related]
23. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.
Daw K; Powers AC
Diabetes; 1995 Feb; 44(2):216-20. PubMed ID: 7532143
[TBL] [Abstract][Full Text] [Related]
24. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65.
Reijonen H; Daniels TL; Lernmark A; Nepom GT
Diabetes; 2000 Oct; 49(10):1621-6. PubMed ID: 11016444
[TBL] [Abstract][Full Text] [Related]
25. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes.
Ziegler B; Strebelow M; Rjasanowski I; Schlosser M; Ziegler M
Autoimmunity; 1998; 28(2):61-8. PubMed ID: 9771977
[TBL] [Abstract][Full Text] [Related]
26. Two amino acids in glutamic acid decarboxylase act in concert for maintenance of conformational determinants recognised by Type I diabetic autoantibodies.
Tree TI; Morgenthaler NG; Duhindan N; Hicks KE; Madec AM; Scherbaum WA; Banga JP
Diabetologia; 2000 Jul; 43(7):881-9. PubMed ID: 10952461
[TBL] [Abstract][Full Text] [Related]
27. Antigenic determinants to GAD autoantibodies in patients with type 1 diabetes with and without autoimmune thyroid disease.
Park H; Yu L; Kim T; Cho B; Kang J; Park Y
Ann N Y Acad Sci; 2006 Oct; 1079():213-9. PubMed ID: 17130557
[TBL] [Abstract][Full Text] [Related]
28. Multiplicity of the antibody response to GAD65 in Type I diabetes.
Gilliam LK; Binder KA; Banga JP; Madec AM; Ortqvist E; Kockum I; Luo D; Hampe CS
Clin Exp Immunol; 2004 Nov; 138(2):337-41. PubMed ID: 15498046
[TBL] [Abstract][Full Text] [Related]
29. GAD65 as a prototypic autoantigen.
Fenalti G; Rowley MJ
J Autoimmun; 2008 Nov; 31(3):228-32. PubMed ID: 18514483
[TBL] [Abstract][Full Text] [Related]
30. Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition.
Primo ME; Anton EA; Villanueva AL; Poskus E; Ermácora MR
Clin Immunol; 2003 Jul; 108(1):38-45. PubMed ID: 12865069
[TBL] [Abstract][Full Text] [Related]
31. Epitope analysis of GAD65Ab using fusion proteins and rFab.
Binder KA; Banga JP; Madec AM; Ortqvist E; Luo D; Hampe CS
J Immunol Methods; 2004 Dec; 295(1-2):101-9. PubMed ID: 15627615
[TBL] [Abstract][Full Text] [Related]
32. Characterisation of an autoreactive conformational epitope on GAD65 recognised by the human monoclonal antibody b78 using a combination of phage display, in vitro mutagenesis and molecular modelling.
O'Connor KH; Banga JP; Darmanin C; El-Kabbani O; Mackay IR; Rowley MJ
J Autoimmun; 2006 May; 26(3):172-81. PubMed ID: 16564157
[TBL] [Abstract][Full Text] [Related]
33. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs.
Padoa CJ; Banga JP; Madec AM; Ziegler M; Schlosser M; Ortqvist E; Kockum I; Palmer J; Rolandsson O; Binder KA; Foote J; Luo D; Hampe CS
Diabetes; 2003 Nov; 52(11):2689-95. PubMed ID: 14578287
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus.
Falorni A; Gambelunghe G; Forini F; Kassi G; Cosentino A; Candeloro P; Bolli GB; Brunetti P; Calcinaro F
J Clin Endocrinol Metab; 2000 Jan; 85(1):309-16. PubMed ID: 10634404
[TBL] [Abstract][Full Text] [Related]
35. Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.
Hampe CS; Radtke JR; Wester A; Carlsson A; Cedervall E; Jönsson B; Ivarsson SA; Elding Larsson H; Larsson K; Lindberg B; Neiderud J; Rolandsson O; Lernmark Å
Diabet Med; 2019 Nov; 36(11):1375-1383. PubMed ID: 30264481
[TBL] [Abstract][Full Text] [Related]
36. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase.
Schwartz HL; Chandonia JM; Kash SF; Kanaani J; Tunnell E; Domingo A; Cohen FE; Banga JP; Madec AM; Richter W; Baekkeskov S
J Mol Biol; 1999 Apr; 287(5):983-99. PubMed ID: 10222205
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the islet cell antibody pattern of monoclonal glutamic acid decarboxylase antibodies recognizing linear and conformational epitopes.
Augstein P; Schlosser M; Ziegler B; Hahmann J; Mauch L; Ziegler M
Acta Histochem; 1996 Apr; 98(2):229-41. PubMed ID: 8739307
[TBL] [Abstract][Full Text] [Related]
38. Conformation-dependent GAD65 autoantibodies in diabetes.
Luo D; Gilliam LK; Greenbaum C; Bekris L; Hampe CS; Daniels T; Richter W; Marcovina SM; Rolandsson O; Landin-Olsson M; Kockum I; Lernmark A
Diabetologia; 2004 Sep; 47(9):1581-91. PubMed ID: 15365614
[TBL] [Abstract][Full Text] [Related]
39. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients.
Raju R; Foote J; Banga JP; Hall TR; Padoa CJ; Dalakas MC; Ortqvist E; Hampe CS
J Immunol; 2005 Dec; 175(11):7755-62. PubMed ID: 16301686
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM.
Falorni A; Ackefors M; Carlberg C; Daniels T; Persson B; Robertson J; Lernmark A
Diabetologia; 1996 Sep; 39(9):1091-8. PubMed ID: 8877294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
